Bioventix

The Company is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company uses its technology in the fields of clinical diagnostics. Its develops products for Thyroid, Fertility, Oncology, Vitamin D, Drugs of Abuse and other diseases. Its product, Vitamin D SMA is a steroid hormone involved in the intestinal absorption of calcium and the regulation of calcium homeostasis but it has also evolved into a hormone that has a diversity of biologic effects.
Company Growth (employees)
Type
Public
HQ
Farnham, GB
Size (employees)
14 (est)+8%
Bioventix is headquartered in Farnham, GB

Bioventix Office Locations

Bioventix has an office in Farnham
Farnham, GB (HQ)
East St

Bioventix Data and Metrics

Bioventix Financial Metrics

Bioventix's revenue was reported to be £5.5 m in FY, 2016 which is a 27% increase from the previous period.
GBP

Revenue (FY, 2016)

5.5 m

Revenue growth (FY, 2015 - FY, 2016), %

27%

Gross profit (FY, 2016)

5 m

Gross profit margin (FY, 2016), %

91%

Net income (FY, 2016)

3.5 m

Market capitalization (24-Jul-2017)

97.7 m

Closing share price (24-Jul-2017)

18.5

Cash (30-Jun-2016)

5.4 m
Bioventix's current market capitalization is £97.7 m.
GBPFY, 2014FY, 2015FY, 2016

Revenue

3.5 m4.3 m5.5 m

Revenue growth, %

23%27%

Cost of goods sold

302.9 k320.5 k494.9 k

Gross profit

3.2 m4 m5 m

Gross profit Margin, %

91%93%91%

Operating expense total

1 m915.2 k816.9 k

Pre tax profit

2.2 m3.1 m4.2 m

Net Income

1.8 m2.6 m3.5 m
GBPFY, 2014FY, 2015FY, 2016

Cash

3.4 m4.1 m5.4 m

Accounts Receivable

322.2 k389.1 k435.6 k

Current Assets

5.3 m6.4 m8.3 m

PP&E

419.7 k487.8 k510.4 k

Total Assets

5.8 m6.9 m8.8 m

Accounts Payable

29.2 k58.4 k22.1 k

Current Liabilities

530.9 k297.5 k549.9 k

Total Liabilities

530.9 k317.8 k567.9 k

Retained Earnings

894 k1.3 m1.6 m

Total Equity

5.2 m6.6 m8.2 m

Financial Leverage

1.1 x1 x1.1 x
GBPFY, 2014FY, 2015FY, 2016

Cash From Operating Activities

1.8 m2.9 m3.7 m

Cash From Financing Activities

58.7 k21 k

Income Taxes Paid

(415.2 k)(548.2 k)(724.5 k)
Y, 2016

Financial Leverage

1.1 x

Bioventix Market Value History

Bioventix Revenue Breakdown

Bioventix Company Life and Culture

You may also be interested in